313950-40-2

Upstream product

• 24424-99-5 di-tert-butyl dicarbonate 
• 201667-18-7 2-Benzyl-2,3-dihydro-1H-pyridin-4-one 
• 212307-73-8 2-Benzyl-4-oxo-3,4-dihydro-2H-pyridine-1-carboxylic acid phenyl ester 
• 626-64-2 pyridin-4-ol 
• 762-75-4 tert-butyl formate 
• 1589-82-8 phenylmagnesium bromide 
• 332940-69-9 tert-butyl 4-oxopyridine-1-carboxylate 
• 620-08-6 4-methoxypyridine 
• 865-47-4 potassium tert-butylate 

Downstream Products

• 313950-46-8 2-Benzyl-4-[1-ethoxycarbonyl-meth-(E)-ylidene]-piperidine-1-carboxylic acid tert-butyl ester 
• 313950-43-5 2-Benzyl-4-[1-phenyl-meth-(E)-ylidene]-piperidine-1-carboxylic acid tert-butyl ester 
• 193480-28-3 (+/-)-1,1-dimethylethyl 4-oxo-2-(phenylmethyl)-1-piperidinecarboxylate 

Relevant academic research and scientific papers

Conjugate addition reactions of N -carbamoyl-4-pyridones and 2,3-dihydropyridones with grignard reagents in the absence of Cu(I) Salts

N-Boc- and N-ethoxycarbonyl-4-pyridones and the resulting 2,3-dihydropyridones undergo 1,4-addition reactions with Grignard reagents in the presence of chlorotrimethylsilane (TMSCl) or BF3·Et 2O in excellent yields. Copper catalysis is not required, and mechanistic considerations suggest that the reaction is proceeding by a conjugate addition pathway rather than by a pathway involving 1,2-addition to an intermediate pyridinium ion. TMSCl-mediated conjugate addition of Grignard reagents to 2-substituted-2,3-dihydropyridones gives the trans-2,6-disubstitued piperidinones stereoselectively, while cuprate reagents give either the trans or cis diastereomers or mixtures.

ORGANIC COMPOUNDS

The present invention provides a compound of formula (I): wherein the variants R1, R2, R3, R4, R5, R6, R7 are as defined herein, and wherein said compound is an inhibitor of CETP, and thus can be employed for the treatment of a disorder or disease mediated by CETP or responsive to the inhibition of CETP.

AMINO-PIPERIDINE DERIVATIVES AS CETP INHIBITORS

The present invention provides a compound of formula (I), wherein the variants R1, R2, R3, R4, R5, R6, R7 are as defined herein, and wherein said compound is an inhibitor of CETP, and thus can be employed for the treatment of a disorder or disease mediated by CETP or responsive to the inhibition of CETP.

A diastereoselective synthesis of 2,4-disubstituted piperidines: scaffolds for drug discovery.

A method for the diastereoselective synthesis of 2,4-disubstituted piperidines has been developed which enables the complete control of reaction selectivity merely by changing the order of the reaction sequence. These targets provide convenient platforms